These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1565 related articles for article (PubMed ID: 31071448)

  • 1. CRISPR/Cas9-based epigenome editing: An overview of dCas9-based tools with special emphasis on off-target activity.
    Tadić V; Josipović G; Zoldoš V; Vojta A
    Methods; 2019 Jul; 164-165():109-119. PubMed ID: 31071448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Harnessing targeted DNA methylation and demethylation using dCas9.
    Pflueger C; Swain T; Lister R
    Essays Biochem; 2019 Dec; 63(6):813-825. PubMed ID: 31724704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Active fusions of Cas9 orthologs.
    Josipović G; Zoldoš V; Vojta A
    J Biotechnol; 2019 Aug; 301():18-23. PubMed ID: 31158410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenome editing of the CFTR-locus for treatment of cystic fibrosis.
    Kabadi AM; Machlin L; Dalal N; Lee RE; McDowell I; Shah NN; Drowley L; Randell SH; Reddy TE
    J Cyst Fibros; 2022 Jan; 21(1):164-171. PubMed ID: 34049825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CRISPR-based epigenome editing: mechanisms and applications.
    Fadul SM; Arshad A; Mehmood R
    Epigenomics; 2023 Nov; 15(21):1137-1155. PubMed ID: 37990877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protocol for Allele-Specific Epigenome Editing Using CRISPR/dCas9.
    Rajaram N; Bashtrykov P; Jeltsch A
    Methods Mol Biol; 2024; 2842():179-192. PubMed ID: 39012596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stabilization of Foxp3 expression by CRISPR-dCas9-based epigenome editing in mouse primary T cells.
    Okada M; Kanamori M; Someya K; Nakatsukasa H; Yoshimura A
    Epigenetics Chromatin; 2017; 10():24. PubMed ID: 28503202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo epigenome editing and transcriptional modulation using CRISPR technology.
    Lau CH; Suh Y
    Transgenic Res; 2018 Dec; 27(6):489-509. PubMed ID: 30284145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR/Cas mediated epigenome editing for cancer therapy.
    Ansari I; Chaturvedi A; Chitkara D; Singh S
    Semin Cancer Biol; 2022 Aug; 83():570-583. PubMed ID: 33421620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent trends in CRISPR-Cas system: genome, epigenome, and transcriptome editing and CRISPR delivery systems.
    Bae T; Hur JW; Kim D; Hur JK
    Genes Genomics; 2019 Aug; 41(8):871-877. PubMed ID: 31119685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of Cell Lines Stably Expressing a dCas9-Fusion or sgRNA to Address Dynamics of Long-Term Effects of Epigenetic Editing.
    Sarno F; Koncz M; Eilers RE; Verschure PJ; Rots MG
    Methods Mol Biol; 2024; 2842():289-307. PubMed ID: 39012602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR/Cas9 Epigenome Editing Potential for Rare Imprinting Diseases: A Review.
    Syding LA; Nickl P; Kasparek P; Sedlacek R
    Cells; 2020 Apr; 9(4):. PubMed ID: 32316223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Notes on Functional Modules in the Assembly of CRISPR/Cas9-Mediated Epigenetic Modifiers.
    Kondrashov A; Karpova E
    Methods Mol Biol; 2021; 2198():401-428. PubMed ID: 32822047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Harnessing CRISPR-Cas9 for Epigenetic Engineering.
    Guerra-Resendez RS; Hilton IB
    Methods Mol Biol; 2022; 2518():237-251. PubMed ID: 35666449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Points of View on the Tools for Genome/Gene Editing.
    Chuang CK; Lin WM
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review on CRISPR/Cas-based epigenetic regulation in plants.
    Jogam P; Sandhya D; Alok A; Peddaboina V; Allini VR; Zhang B
    Int J Biol Macromol; 2022 Oct; 219():1261-1271. PubMed ID: 36057300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishment of Cell Lines Stably Expressing dCas9-Fusions to Address Kinetics of Epigenetic Editing.
    Goubert D; Koncz M; Kiss A; Rots MG
    Methods Mol Biol; 2018; 1767():395-415. PubMed ID: 29524148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR/Cas9-Based Engineering of the Epigenome.
    Pulecio J; Verma N; Mejía-Ramírez E; Huangfu D; Raya A
    Cell Stem Cell; 2017 Oct; 21(4):431-447. PubMed ID: 28985525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Near-infrared optogenetic engineering of photothermal nanoCRISPR for programmable genome editing.
    Chen X; Chen Y; Xin H; Wan T; Ping Y
    Proc Natl Acad Sci U S A; 2020 Feb; 117(5):2395-2405. PubMed ID: 31941712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenome editing by CRISPR/Cas9 in clinical settings: possibilities and challenges.
    Pei WD; Zhang Y; Yin TL; Yu Y
    Brief Funct Genomics; 2020 May; 19(3):215-228. PubMed ID: 31819946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 79.